Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1320375,
author = {Kolek, Vitezslav and Pesek, Milos and Skřičková, Jana and Grygarkova, Ivona and Roubec, Jaromir and Koubkova, Leona and Cernovska, Marketa and Hejduk, Karel},
booktitle = {16th World Conference on Lung Cancer},
keywords = {ALK gene; crizotinib; survival; advanced NSCLC},
language = {eng},
title = {Czech Experience with Crizotinib in the Personalized Treatment of NSCLC},
year = {2015}
}
TY - CONF
ID - 1320375
AU - Kolek, Vitezslav - Pesek, Milos - Skřičková, Jana - Grygarkova, Ivona - Roubec, Jaromir - Koubkova, Leona - Cernovska, Marketa - Hejduk, Karel
PY - 2015
TI - Czech Experience with Crizotinib in the Personalized Treatment of NSCLC
KW - ALK gene
KW - crizotinib
KW - survival
KW - advanced NSCLC
N2 - Background: Crizotinib is a highly selective drug used in the treatment of anaplastic lymphoma kinase (ALK) gene re-arrangement positive non-small cell lung cancer (NSCLC). In the Czech Republic it was used in frame of compassionate cases program and now is reimbursed in pretreated tumors with EML 4/ALK gen translocation verified by FISH and/or IHC testing. The recommended dose is 250 mg bid/ day. Crizotinib is used since 2011, data are evaluated according to the National Reference Centre Registry. Methods: Present study evaluates 26 patients (pts), 14 males,12 females with mean age 60 (31- 75) years. Out of them 11 (42.3%) were non-smokers, 8 (30.8%) ex-smokers and 7 (26.9 %) smokers. All of them had NSCLC with EML4/ALK gene translocation, 23 had adenocarcinoma, two NOS and one patient had adenosquamous cancer. Stage in the time of treatment was IIIB in 3 and IV in 23 pts. Crizotinib was applied in 2nd line in 17 pts, 3rd line in 5 pts, 4th line in 3 pts, 5th in one patient. PS was 0 in 3 pts, 1 in 20 pts and 2 in 3 pts. Results: On the date of evaluation, 14 pts continued the treatment, 6 died and 6 stopped treatment due to progression. Crizotinib effectiveness was assessed in 15 pts: CR in 3 (20%) pts, PR in 3 (20%) pts, SD in 5 (33.3 %) pts, DP in 4 (26.7 %) pts. CR was associated with long response duration (10.7, 31.8, 34.1 months). Grade 3 adverse events (gastrointenstinal discomfort and liver disease) were observed in two (7.7 %) pts, grade 2 problems with visus appeared in two patients. Dose of crizotinib was reduced in 3 pts. Median of progression free survival was 15 months, median of overall survival was not reached. Conclusion: Interim analysis of present series shows, that crizotinib has very good tolerability and promising effectiveness even in heavily pretreated patients with EML4/ALK gene translocation. Long term survival analysis is running.
ER -
KOLEK, Vitezslav, Milos PESEK, Jana SKŘIČKOVÁ, Ivona GRYGARKOVA, Jaromir ROUBEC, Leona KOUBKOVA, Marketa CERNOVSKA a Karel HEJDUK. Czech Experience with Crizotinib in the Personalized Treatment of NSCLC. In \textit{16th World Conference on Lung Cancer}. 2015. ISSN~1556-0864.
|
